S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
NASDAQ:HBIO

Harvard Bioscience - HBIO Stock Forecast, Price & News

$2.96
+0.09 (+3.14%)
(As of 01/27/2023 08:55 PM ET)
Add
Compare
Today's Range
$2.83
$3.00
50-Day Range
$2.12
$2.96
52-Week Range
$1.98
$6.49
Volume
47,100 shs
Average Volume
79,167 shs
Market Capitalization
$123.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Harvard Bioscience MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
35.1% Upside
$4.00 Price Target
Short Interest
Healthy
0.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.08mentions of Harvard Bioscience in the last 14 days
Based on 27 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.03) to $0.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Computer And Technology Sector

118th out of 630 stocks

Analytical Instruments Industry

5th out of 28 stocks


HBIO stock logo

About Harvard Bioscience (NASDAQ:HBIO) Stock

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Stock News Headlines

Yale at Harvard odds, tips and betting trends
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Harvard hosts Dingle and Pennsylvania
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Harvard researchers reverse aging in mice
Harvard at Pennsylvania odds, tips and betting trends
Harvard wins 95-89 against Cornell
See More Headlines
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Company Calendar

Last Earnings
11/08/2022
Today
1/30/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
475
Year Founded
1901

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+35.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-290,000.00
Pretax Margin
-6.07%

Debt

Sales & Book Value

Annual Sales
$118.90 million
Cash Flow
$0.38 per share
Book Value
$2.04 per share

Miscellaneous

Free Float
39,075,000
Market Cap
$123.31 million
Optionable
Optionable
Beta
1.63

Social Links


Key Executives

  • James W. GreenJames W. Green
    Chairman, President & Chief Executive Officer
  • Jennifer Cote
    Chief Financial Officer & Treasurer
  • Ryan Wallace
    Vice President-Global Sales, Preclinical Systems
  • Jacques Coumans
    Chief Marketing Officer
  • John J. Fry
    Secretary & Chief Legal Counsel













HBIO Stock - Frequently Asked Questions

Should I buy or sell Harvard Bioscience stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HBIO shares.
View HBIO analyst ratings
or view top-rated stocks.

What is Harvard Bioscience's stock price forecast for 2023?

1 equities research analysts have issued 1-year target prices for Harvard Bioscience's shares. Their HBIO share price forecasts range from $3.00 to $5.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 35.1% from the stock's current price.
View analysts price targets for HBIO
or view top-rated stocks among Wall Street analysts.

How have HBIO shares performed in 2023?

Harvard Bioscience's stock was trading at $2.77 at the start of the year. Since then, HBIO stock has increased by 6.9% and is now trading at $2.96.
View the best growth stocks for 2023 here
.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 265,600 shares, a decrease of 32.6% from the December 31st total of 394,100 shares. Based on an average trading volume of 137,800 shares, the days-to-cover ratio is presently 1.9 days. Currently, 0.7% of the shares of the stock are sold short.
View Harvard Bioscience's Short Interest
.

When is Harvard Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our HBIO earnings forecast
.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) issued its quarterly earnings data on Tuesday, November, 8th. The medical instruments supplier reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by $0.05. The medical instruments supplier had revenue of $26.92 million for the quarter, compared to analyst estimates of $28 million. Harvard Bioscience had a positive trailing twelve-month return on equity of 4.00% and a negative net margin of 5.84%.

What guidance has Harvard Bioscience issued on next quarter's earnings?

Harvard Bioscience updated its fourth quarter 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $30.00 million-$30.00 million, compared to the consensus revenue estimate of $32.78 million.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by many different retail and institutional investors. Top institutional investors include AMH Equity Ltd (5.41%) and Greenwood Capital Associates LLC (0.68%). Insiders that own company stock include Alan I Edrick, Bertrand Loy, James W Green and James W Green.
View institutional ownership trends
.

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $2.96.

How much money does Harvard Bioscience make?

Harvard Bioscience (NASDAQ:HBIO) has a market capitalization of $123.31 million and generates $118.90 million in revenue each year. The medical instruments supplier earns $-290,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does Harvard Bioscience have?

The company employs 475 workers across the globe.

Does Harvard Bioscience have any subsidiaries?
The following companies are subsidiares of Harvard Bioscience: Data Sciences International.
Read More
How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The official website for the company is www.harvardbioscience.com. The medical instruments supplier can be reached via phone at (508) 893-8999, via email at info@harvardbioscience.com, or via fax at 508-429-5732.

This page (NASDAQ:HBIO) was last updated on 1/30/2023 by MarketBeat.com Staff